Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 13,900 shares, a decrease of 47.1% from the May 15th total of 26,300 shares. Based on an average daily trading volume, of 24,200 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.4% of the company’s stock are short sold.
Assembly Biosciences Price Performance
Shares of ASMB opened at $16.85 on Monday. The business’s fifty day moving average price is $12.64 and its 200 day moving average price is $13.21. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $19.93. The stock has a market capitalization of $128.70 million, a PE ratio of -2.70 and a beta of 0.55.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.01) by $0.84. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The firm had revenue of $9.42 million for the quarter, compared to analysts’ expectations of $7.41 million. As a group, research analysts anticipate that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Assembly Biosciences
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Guggenheim assumed coverage on Assembly Biosciences in a research note on Tuesday, March 25th. They set a “buy” rating and a $31.00 target price for the company. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, March 24th. Finally, Wall Street Zen cut Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, March 24th.
Check Out Our Latest Analysis on Assembly Biosciences
About Assembly Biosciences
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Recommended Stories
- Five stocks we like better than Assembly Biosciences
- What is the FTSE 100 index?
- RH Stock Rockets on Surprise Profit and Tariff Shift
- How to Invest in Blue Chip Stocks
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What is the Nasdaq? Complete Overview with History
- Alphabet Enters a Bull Market: Is It Time to Buy?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.